Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature

We are reporting on a 14-year-old boy with a very early relapse of pre-B acute lymphoblastic leukemia (ALL) and anaplastic astrocytoma WHO II; the astrocytoma was subtotally resected and subsequently treated with irradiation and chemotherapy. The leukemic relapse was refractory to the administered salvage therapy. Therefore, treatment with the human anti-CD20 monoclonal antibody (MoAb) IDEC-C2B8 (rituximab) was initiated. After a small fraction of the standard dose (375 mg/m²) had been administered, the infusion had to be interrupted because of an acute attack of pain in the lumbar region. Two days later, after resumption of the therapy, he developed a fatal course of systemic inflammatory response syndrome (SIRS) and died, possibly due to uncontrollable cytokine release syndrome associated with sepsis. The fatal course will be discussed based on a review of the literature.

Haematologica 2006; 91(5):e69-e71

The safety and efficacy of the chimeric monoclonal antibody rituximab, which specifically binds to the CD20 antigen on normal and malignant B lymphocytes, has been proven in many clinical trials. The mode of action of rituximab includes complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity.1 The indication for rituximab includes mainly CD20+ Hodgkin- and Non-Hodgkin B-cell lymphoma with a lymphocytosis up to 5000/µL. Only a few cases of treatment of acute lymphoblastic leukemia (ALL) with rituximab have been reported.2,3 Between 84% and 95% of patients experienced treatment-related adverse events, approximately 90% of which were mild to moderate, most involving flu-like symptoms (fever, chills, nausea and asthenia).4 Infusion-related cytokine release syndrome (CRS)5,6 is the most frequent MoAb-specific adverse event of rituximab.4 The vast majority of infusion-related adverse reactions occurred with the first infusion and within the first 24 hrs; therefore close monitoring is imperative.4 The post-marketing surveillance database indicates 0.04-0.07% of patients with a fatal courses related to rituximab administration.7

Case report

We are reporting on a 14-year-old boy without tumor syndromes in the family history suffering from relapse of pre-B ALL and anaplastic astrocytoma WHO III. Initially a pre-B ALL was diagnosed. A noticeable hyperdensity of the left gyrus cinguli in the cerebral MRI was considered as a leukemic infiltration. Combination chemotherapy was commenced according to the German CoALL-06-97 trial (high risk).8 After induction chemotherapy, bone marrow (BM) puncture revealed complete remission but the cerebral lesion showed no change. A stereotactic biopsy confirmed an anaplastic astrocytoma WHO III infiltrating the frontal brain. The tumor was resected incompletely and ALL chemotherapy was switched to mercaptopurine maintenance therapy. Treatment according to the national HIT-GBM-D trial was started.9 Seven months after diagnosis of ALL he suffered a very early relapse. On day 15 of the ALL relapse protocol ALL-REZ BFM 2002,10 BM-puncture revealed 80% lymphoblasts. He was referred to our department to receive rituximab and chemotherapy before BM transplantation. Before the administration of rituximab, he had slightly elevated liver enzymes (ALT 117 U/l [normal <29 U/l]) and moderately elevated plasma LDH (790 U/l [normal < 377 U/l]). PBC showed a WBC of 1.5 /nL with 69% lymphoblasts. The CD-20 surface marker was expressed on 36% of lymphoblasts.

Rituximab (375 mg/m²) infusion was started at 13 mg/h (0.2 mg/kg/h), with the infusion rate progressively increased according to the patient’s clinical condition. This therapy was accompanied by aggressive hydration, diuresis, prednisone, dimetindem maleate, allopurinol, and morphine. Two hours later, after infusion of approximately 75 mg rituximab, the procedure was stopped because the patient complained of intolerable back pain in the lumbar region accompanied by tachycardia (180/min) and slight chills. The patient recovered quickly after the administration of morphine. The next day, after a second dose of morphine the clinical condition was inconsiderably. PBC showed an nearly unchanged WBC of 1.4 /nL, HGB 7.8 mg/dL, PLT 11 /nL and slightly elevated ALT 78 U/L, and elevated plasma LDH 1587 U/L. Two days later, rituximab infusion was resumed at a quarter of the previous infusion rate. After 9 hrs and infusion of approximately 230 mg rituximab, the patient developed an anaphylactoid reaction with arterial hypotension, tachycardia, and hypoxia. Adrenalin, dimetindem maleate, glucocorticoids, oxygen, and fluids were given and he was transferred to the ICU. Leukocytes were 0.3/nl with 7 % lymphoblasts, serum LDH rose to 2231 U/l, plasma ALT rose to 222 U/l [normal < 29 U/l], plasma AST rose to 309 U/l [normal < 23 U/l], plasma GGT rose to 80 U/L [normal < 48 U/l] and potassium was 2.7 mmol/l without other signs of tumor lysis syndrome (TLS).

Despite maximal intensive care support, hypotonia persisted and echocardiography revealed severely restricted left ventricular function (fractional shortening 21–23%). Vancomycin and cefotaxime were given because of suspected septicaemia with leukocytopenia, fever and rising C-reactive protein (24 mg/dL). Even though the detected causative organisms (Streptococcus bovis and E. coli.) were sensitive towards the administered antibiotics, the patient’s clinical condition deteriorated and he died of multiple organ failure 72 hrs after administration of the first dose of rituximab. The autopsy failed to provide any additional information beyond evidence of fat-embolism of the lungs and petechial bleedings in the skin, the mucous membranes, the peri- and epicard, the lungs, and the brain. Astrocytoma was infiltrating the corpus callosum and the fornix.

Search strategy and selection criteria

Published data for this review were identified by searches of NCBI PubMed over the past 15 years using CD20 monoclonal antibody, rituximab, cytokine release syndrome as keywords without any restrictions on language of publication. Also, references to relevant articles in the authors’ own and the manufacturer’s databases were used.

Review of literature

Rituximab therapy is associated with possible adverse events like tumor lysis syndrome (TLS) or cytokine-release syndrome (CRS) (see Table 1). Patients with high cell counts and a high mitotic index are at high risk for TLS after any kind of cytoreductive therapy in cases of...
leukemia or lymphoma. In the literature, rituximab has been held responsible for both severe and moderate courses of TLS. Besides TLS, the most predictable MoAb-specific side effects are systemic flu-like symptoms, headache, fever, sweat, skin rash, shortness of breath, hypotenion, nausea, and asthenia. In general, CRS known from therapy with MoAbs occurs mostly during the first infusion of MoAbs.11 Severe hypotenion, bronchospasm and hypoxia leading to death have been reported. The pathophysiology of these reactions appear to be related to CRS, potentially leading to cytokine-associated systemic inflammatory response syndrome (SIRS). Clinically severe courses of CRS21 after MoAbs therapy are known from similar agents like Muronab and Basiliximab. The underlying mechanism of CRS is related to changes of serum cytokine levels due to rapid injection of the antibody. CRS is characterized by an increase of inflammatory cytokines such as IFN-γ, IL-8 and TNF-α occurring about 90 min after the first infusion. In severe cases of CRS after rituximab, a 5 to 10-fold increase in liver enzymes, elevation of d-dimers, lactate dehydrogenase and prolongation of prothrombin time are also commonly observed.20 Patients with peripherally higher number of tumor cells (>50×10⁹/l) are more likely to develop severe infusion-related reactions including fever, chills, nausea, dyspnea and hypotension. Data on treatment with rituximab in children suffering from ALL are scant.22,23 Lim et al. report on a fatal CRS in a 71-year-old woman with Rai stage I B-cell chronic lymphocytic leukemia (B-CLL) and high leukemic cell burden. She was started on rituximab at a very low initial dose. After a gradual increase during the second hour, she experienced rigor. Dispite discontinuation of rituximab infusion, she became hypotensive with mild breathlessness and basal pulmonary crepitations. The patient suffered from progressive cardiopulmonary deterioration and died of cardiopulmonary collapse without signs of a TLS 9 hrs after administration of rituximab.

Kunzman et al. report on a 65-year-old man with pretreated B-CLL and high circulating lymphocyte counts. Refractory to standard chemotherapy, he was admitted for rituximab therapy. Pretreatment WBC was 271.0 nl. Because of the high leukemic cell burden, the antibody was started at a reduced infusion rate of 2.5 mg/h for the first 2 hrs and gradually increased. After 6.5 hrs, the patient developed tachycardia, acetonopen-resistant fever, and chills with decline of WBC. Rituximab therapy was discontinued. Unfortunately, three hours after cessation, the clinical condition deteriorated with progressive hypotenion, dyspnea, tachypnea, and hypoxemia with basal crepitations in his lungs, progressive confusion and enuresis. In spite of intensive care support, the patient died of cardiopulmonary failure 13 hrs after initiation of rituximab infusion. Based on histopathologic findings, the authors provide evidence that tumor cell agglutination could have been responsible for severe infusion-related adverse events during rituximab treatment.

**Table 1. Case reports on fatal courses after rituximab.**

| B-Cell NHL | TLS | Abou Moudar Y et al.12 |
| B-cell CLL | CRS | Lim LC et al.18 |
| B-Cell NHL | CRS ?? | Nikolaidis15 |
| B-Cell NHL | Tumor cell agglutination | Kunzman et al.17 |

**Discussion**

Although the efficiency of rituximab is not clearly proven in ALL we decided to make a therapeutic attempt in face of the desperate condition of our patient. The exact mechanism and cause of the fatal progressive course after rituximab cannot clearly be explained. The reason for the massive back pain attack after the first infusion of rituximab remains unclear. After the second infusion, there was no evidence of TLS or massive leukemic cell agglutination. Therefore, it seems plausible that our patient sustained progressive CRS leading to a fatal SIRS. In severe cases of CRS after rituximab a 5 to 10-fold increase of liver enzymes, lactate dehydrogenase and a often a prolonged prothrombine time have been described. In our patient, we observed a 10-fold increase of liver enzymes and lactate dehydrogenase. The prothrombine time was normal possibly due to the administration of fresh frozen plasma. However, the circumstantial course remains vague. In addition, rituximab-induced leukokytopenia could have promoted a systemic infection as indicated by increasing CRP and the detection of Streptococcus bovis and E. coli. A contradiction to this assumption would be the fact that in vitro tested antibiotics were not effective.

In our opinion, the most likely explanation for the unexpected fatal course is a SIRS on the basis of a massive CRS, potentially in combination with septicemia. Unfortunately, no serum-cytokine levels were measured in order to support the evidence of a CRS. In contrast to our patient, it is reported that rituximab-related CRS occurs mainly with the first infusion and within the first 24 hrs. Hence, it is essential that the infusion-related reaction be monitored continuously even though the manufacturer’s post-marketing surveillance database indicates that just 0.04–0.07% of patients will experience a fatal course related to rituximab administration.

**Key words: Antibodies, monoclonal, adverse event, cytokine release syndrome, cytokines secretion, fatal outcome, acute lymphoblastic leukemia, drug therapy, immunology**

*contributed equally

Correspondence: Georg Seifert
Charité, Universitätsmedizin Berlin, Germany
Otto-Hauber Center for Pediatric and Adolescent Medicine (OHC) Department of Pediatric Oncology/Hematology
Charité - Universitätsmedizin Berlin Otto-Hauben-Centrum für Kinder- und Jugendmedizin Klinik für Pädiatrie mit Schwerpunkt Hämatologie / Hämatologie Augustenburger Platz 1 13353 Berlin Germany
+49-30-450 666087 +49-30-450 566946
E-mail: georg.seifert@charite.de

**References**


